DINUTUXIMAB
- UNII: 7SQY4ZUD30
- Preferred Substance Name: DINUTUXIMAB
- 1363687-32-4
- APN311
- APN-311
- CH14.18
- CH-14.18
- CH14.18-UTC
- CH-14.18-UTC
- CH1418
- CH-1418
- CHIMERIC ANTI-DISIALOGANGLIOSIDE (GD2) MONOCLONAL ANTIBODY (CH14.18/CHO)
- DINUTUXIMAB [INN]
- DINUTUXIMAB [JAN]
- DINUTUXIMAB [MI]
- DINUTUXIMAB [PURPLE BOOK CDER]
- DINUTUXIMAB [USAN]
- DINUTUXIMAB [WHO-DD]
- DINUTUXIMAB BETA
- DINUTUXIMAB BETA [INN]
- DINUTUXIMAB BETA [WHO-DD]
- IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CH14.18 LIGHT CHAIN, DIMER
- IMMUNOGLOBULIN G1, ANTI-(GANGLIOSIDE GD2) (HUMAN-MUS MUSCULUS MONOCLONAL CH14.18/CHO HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CH14.18/CHO LIGHT CHAIN, DIMER
- QARZIBA
- UNITUXIN
About, Contact Us, Copyright, Privacy, Accessibility
U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002
U.S. Food and Drug Administration, Health & Human Services
Powered by
